May 22nd 2025
Patients with extensive-stage small cell lung cancer (SCLC) experienced clinically meaningful benefits with lurbinectedin plus atezolizumab vs atezolizumab in the phase 3 IMforte trial, according to findings being presented at the ASCO Annual Meeting.
Watch the series now!
Reducing Radiation Dose in Oropharynx Cancer Can Improve QOL
Expert Insights: Most Popular Videos, Interviews, and Podcasts in 2016
Dr Joseph Alvarnas Discusses Clinical Risk in Value-Based Cancer Care
How Can Practices Seek Success With Oncology Payment Reform?
Preventing Chemotherapy-Associated Alopecia: A Case for Palliation?